Introduction
============

β-thalassemia major is hemolytic anemia caused by inhibition of the synthesis of the β-globin peptide chain, caused by gene mutation.[@b1-mjhid-11-1-e2019036] β-thalassemia major patients are homo- or double-heterozygous (beta0/beta0 or beta+/beta+ or beta0/beta+), whose parents are carriers of the β-thalassemia gene (beta0 or beta+).[@b2-mjhid-11-1-e2019036],[@b3-mjhid-11-1-e2019036] Approximately 1.5% of the world's population carries the β-thalassemia gene, and the number of newborns diagnosed with homo- or double-heterozygous β-thalassemia every year exceeds 200,000.[@b4-mjhid-11-1-e2019036],[@b5-mjhid-11-1-e2019036] A survey on 600,000 people in China in the 1980s showed an average prevalence rate of β-thalassemia of 0.67%,[@b6-mjhid-11-1-e2019036] reaching almost 2% in some instances.[@b7-mjhid-11-1-e2019036] This disease causes from 50,000 to 100,000 deaths per year, or from 0.5% to 0.9% of all deaths of children under five years of age in low-income or middle-income countries.[@b8-mjhid-11-1-e2019036]

Patients with β-thalassemia major usually suffer from anemia throughout their lives. Moreover, they need a long-term regular blood transfusion to attenuate anemia and reduce mortality.[@b1-mjhid-11-1-e2019036],[@b9-mjhid-11-1-e2019036] Unfortunately, the human body does not have an iron excretory pathway, which leads to the accumulation of iron from the transfused blood, known as iron overloaded. The excessive iron is then deposited in the heart, liver, endocrine glands, and other organs, causing heart failure, liver damage, diabetes, hypogonadism, thyroid dysfunction, *etc*., eventually leading to death.[@b9-mjhid-11-1-e2019036] Drug therapy with iron chelators is the only treatment used to clear the excessive iron from the body and reduce the end-organs damage and associated mortality. Three iron chelators have been licensed worldwide: Deferoxamine (DFO), Deferiprone (DFP), and Deferasirox (DFX).[@b1-mjhid-11-1-e2019036],[@b9-mjhid-11-1-e2019036]

DFO appeared into the market in the 1970s and is the first-line drug for iron overload. The usual dose of DFO is 50 mg/Kg once a day. DFO is administered as a subcutaneous infusion for 8--12 h, 5--7 times per week, due to its short plasma half-life (20--30 min) and absence of oral activity.[@b10-mjhid-11-1-e2019036]--[@b12-mjhid-11-1-e2019036] The life quality and compliance of patients are reduced by these lengthy infusions. Low compliance with DFO has a higher risk of iron overload-related complications and death.[@b13-mjhid-11-1-e2019036] A literature review has shown that the rate of patients with good compliance had a 36% lower incidence of cardiac complications than patients with low compliance, and the RR for mortality of non-compliant group versus compliant group was 12.6.[@b14-mjhid-11-1-e2019036] To overcome the disadvantages of DFO treatment, oral iron chelators, including DFP and DFX, were introduced.

DFP is a second-line drug, which means that when patients are unable to use DFO or are dissatisfied with the efficacy of DFO, they can use DFP. The usual dose of DFP is 75--100 mg/Kg once a day in three separate doses. DFP exists under the form of tablets and oral solution, and the latter can be used in one-year-old children. The common adverse reactions of DFP are gastrointestinal discomfort, arthralgia, joint effusion, vomiting, and zinc deficiency.[@b15-mjhid-11-1-e2019036] Moreover, the severe adverse reactions of the treatment with DFP are neutropenia and agranulocytosis.[@b16-mjhid-11-1-e2019036] To reduce the risk of agranulocytosis, patients who are using DFP need weekly blood cell count tests.

DFX is the latest oral iron chelator and is mainly used in patients aged two years and older. The usual dose of DFX is 20--40 mg/Kg once a day. The common adverse reactions of DFX are the following: gastrointestinal symptoms, rash, serum creatinine increased, and alanine aminotransferase increased.[@b15-mjhid-11-1-e2019036],[@b17-mjhid-11-1-e2019036],[@b18-mjhid-11-1-e2019036] Moreover, the severe adverse reactions of DFX treatment are renal failure, liver failure, and related death. So it is necessary to make baseline and monthly monitoring of serum creatinine, serum transaminases, and bilirubin.[@b19-mjhid-11-1-e2019036] Pediatric patients need to be focused on. The last study reported that DFX causes acute kidney injury (AKI) in a dose-dependent manner, and pediatric patients face a high risk of AKI and a cycle of repeated kidney injury due to a higher DFX exposure at a given eGRF.[@b20-mjhid-11-1-e2019036] The US Food and Drug Administration recommended dose reduction or interruption when physicians often observed fever or dehydration adverse effects in children receiving DFX.[@b19-mjhid-11-1-e2019036]

The DFO, DFP, and DFX monotherapies can effectively reduce the liver iron concentration (LIC) and serum ferritin level (SFL) to avoid iron overload.[@b21-mjhid-11-1-e2019036],[@b22-mjhid-11-1-e2019036] A meta-analysis of 16 randomized controlled trials showed that three iron chelators monotherapies have the same effect for decreasing LIC, while DFX can reduce SFL more effectively.[@b22-mjhid-11-1-e2019036] Heart disease related to myocardial iron deposition remains a major cause of morbidity and the primary cause of mortality in β-thalassemia major patients.[@b23-mjhid-11-1-e2019036]--[@b25-mjhid-11-1-e2019036] Cardiac complications are reported to be the cause of the deaths in 71% of these patients.[@b26-mjhid-11-1-e2019036],[@b27-mjhid-11-1-e2019036] A multicentre prospective survey showed that DFO, DFP, and DFX monotherapies not only in removing iron from the liver, but also in improving myocardial siderosis and biventricular function.[@b28-mjhid-11-1-e2019036] When the efficacy of DFO or DFP monotherapy is low, combination therapy of DFO and DFP (DFO+DFP) can be used. The Guidelines from the US, Italy, Australia, and China all recommended that β-thalassemia major patients with over iron-related cardiomyopathy should receive DFO+DFP.[@b15-mjhid-11-1-e2019036],[@b29-mjhid-11-1-e2019036]--[@b31-mjhid-11-1-e2019036]

As β-thalassemia major patients need to use iron chelators for their whole life, the treatment cost is astronomic. It causes not only enormous economic pressure on the families of patients but also huge overall socio-economic losses to society as a whole. For example, Sheth *et al*. reported that the annual average treatment cost of adult transfusion-dependent β-thalassemia patients in the United States of America (USA) was United States dollar (USD) 128,062.[@b32-mjhid-11-1-e2019036] Additionally, Esmaeilzadeh *et al*. found that the treatment of the approximately 18,000 β-thalassemia major patients in Iran led to an annual loss of nearly USD 150 million to Iran's health system.[@b33-mjhid-11-1-e2019036] Another study also showed that the annual average treatment cost of β-thalassemia major patients with blood transfusion and iron excretion in China was over the Chinese Yuan (CNY) 100,000, resulting in economic losses of more than CNY 1.4 billion per year.[@b2-mjhid-11-1-e2019036] Therefore, the specific costs and the overall economic burden of the application of different chelation regimens in the treatment of β-thalassemia major areas are of substantial importance.

A large number of pharmacoeconomic studies on chelators in β-thalassemia major patients have been performed worldwide but there was no systematic review to summarize the existing evidence. Meanwhile, some results are inconsistent. In the comparison of DFX versus DFO, Delea *et al*.[@b34-mjhid-11-1-e2019036] thought DFX was cost-effective but Luangasanatip *et al*.[@b35-mjhid-11-1-e2019036] thought the opposite.

Therefore, the authors of this paper systematically reviewed the existing publications in the pharmacoeconomic literature related to the four chelation regimens, DFO or DFP or DFX monotherapy and DFO+DFP. This study aimed to determine the cost-effectiveness of four chelation regimens and provide evidence for the rational use of chelation regimens for β-thalassemia major therapy in the clinic.

Methods
=======

Search strategy
---------------

A systematic literature search in MEDLINE (PubMed),[@b36-mjhid-11-1-e2019036] EMBASE (Ovid),[@b37-mjhid-11-1-e2019036] Cochrane Central Register of Controlled Trials (CENTRAL, Cochrane Library),[@b38-mjhid-11-1-e2019036] Health Technology Assessment Database (HTAD, Cochrane Library),[@b38-mjhid-11-1-e2019036] NHS Economic Evaluation Database (NHS EED, Cochrane Library),[@b38-mjhid-11-1-e2019036] China Biology Medicine (CBM, SinoMed),[@b39-mjhid-11-1-e2019036] China National Knowledge Infrastructure (CNKI),[@b40-mjhid-11-1-e2019036] VIP Data,[@b41-mjhid-11-1-e2019036] and Wanfang Data[@b42-mjhid-11-1-e2019036] were conducted on April 2018, with no restrictions on the date. In addition, a manual search was performed to identify conferences and symposia. Chinese and English search terms were both used. Searches of these databases were performed using Mesh terms such as "thalassaemia", "beta-thalassemia", "iron overload", "iron chelating agents", "deferoxamine", "deferiprone", "deferasirox", "pharmacoeconomics", "cost-benefit analysis", "cost-effectiveness analysis", "cost-utility analysis" and "cost analysis"; other search terms included Cooley's anaemia, Mediterranean anaemia, beta type thalassemia, beta type microcytemia, hemoglobin F disease, erythroblastic anemia, thalassemia major, transfusional hemosiderosis, iron chelate, iron chelating, iron chelation, desferrioxamine, desferrioxamine, Hdmpp, L1, pharmaceutical economics, marginal analysis, cost-benefit, cost comparison, cost-minimization analysis, cost measure, and their variations.

### Inclusion criteria

-   Population: β-thalassemia major patients with chronic iron overload requiring blood transfusions;

-   Intervention: DFO monotherapy or DFP monotherapy or DFX monotherapy, or DFO+DFP;

-   Control: DFO monotherapy or DFP monotherapy DFX monotherapy, or DFO+DFP, or placebo;

-   Outcome: incremental cost-effectiveness ratios (ICER, ICER = incremental cost/incremental effectiveness);

-   Study type: the full economic evaluation studies, including cost-effectiveness analyses (CEA), cost-utility analyses (CUA), cost-benefit analyses (CBA) and cost-minimization analyses (CMA);

### Exclusion criteria

-   Patients with other diseases;

-   Patients with bone marrow transplantation;

-   The language was not Chinese or English;

-   The published study was not with a full text, including abstract, poster, comment, *etc*.

Papers selection and data extraction
------------------------------------

The study selection and data extraction were conducted independently by two researchers. The differences between the decisions of the reviewers were resolved by consensus. All double papers were excluded, and the remaining papers were assessed in a two-stage procedure. Firstly, the title and abstract were screened using the defined inclusion and exclusion criteria. If reviewers could not determine from the abstract and title whether a paper met the eligibility criteria, the paper was excluded. Secondly, the full texts of the remaining papers were assessed for inclusion. Further, we collected the following data from each included paper: (1) Basic information: the first author, year, country, study type, study method, *etc*.; (2) The basic characteristics of patients: age, treatment, *etc*.; (3) Economic parameters: perspective, discount, incremental costs (ΔCOST), incremental quality-adjusted life year (ΔQALY), ICER, payment threshold, *etc*.

Methodological quality assessment
---------------------------------

Two researchers independently assessed the methodological quality of the included papers. Differences in the decisions between the reviewers were resolved by consensus. Each included paper was evaluated using a checklist developed by Drummond *et al*. (the Drummond checklist).[@b43-mjhid-11-1-e2019036] The Drummond checklist consists of 10 questions. Each paper was scored for quality using a scale from 0 to 10 points. If "yes" was the answer to the question, question received a score of 1 point, whereas if the answer was "no" or "uncertain," the score was 0 points. A rating of "A" (9--10 points), "B" (7--8 points), "C" (5--6 points), and "D" (0--4 points) was assigned.[@b44-mjhid-11-1-e2019036]

Results
=======

Search results
--------------

The overall search results and steps with elimination schema are provided in [Figure 1](#f1-mjhid-11-1-e2019036){ref-type="fig"}. The initial number of records was 968, but after evaluation of the abstract and the full text, only eight papers met the final eligibility criteria.[@b34-mjhid-11-1-e2019036],[@b35-mjhid-11-1-e2019036],[@b45-mjhid-11-1-e2019036]--[@b50-mjhid-11-1-e2019036]

Properties of the included papers
---------------------------------

[Table 1](#t1-mjhid-11-1-e2019036){ref-type="table"} provides the characters of the included papers, and [Table 2](#t2-mjhid-11-1-e2019036){ref-type="table"} displays the results of the included studies. Remarkably, one paper[@b49-mjhid-11-1-e2019036] adopted two perspectives for the analysis, including the perspective of the public payer for health services in Poland (Polish National Health Fund, NHF) and the perspective of the patient NHF. However, the results for both perspectives were identical. The three health states in Ho *et al*.[@b47-mjhid-11-1-e2019036] were β-thalassemia with complications, β-thalassemia without complications, and death. The complications included cardiac disease, diabetes mellitus, hypogonadism, hypoparathyroidism, and hypothyroidism.

The cost of three main components was considered in the included papers: direct medical cost, direct non-medical cost, and indirect cost. The different papers have collected different cost data. The specific costs are shown in [Table 1](#t1-mjhid-11-1-e2019036){ref-type="table"} and [Table 2](#t2-mjhid-11-1-e2019036){ref-type="table"}. As can be seen in [Table 2](#t2-mjhid-11-1-e2019036){ref-type="table"}, the costs affecting the economy of the four chelation regimens were predominantly constituted by the chelation cost, DFO administration cost, and indirect cost.

Methodological quality assessment
---------------------------------

The results of the methodological quality assessment using the Drummond checklist are presented in [Table 3](#t3-mjhid-11-1-e2019036){ref-type="table"}. Out of the eight papers, six papers (75.00%)[@b34-mjhid-11-1-e2019036],[@b35-mjhid-11-1-e2019036],[@b46-mjhid-11-1-e2019036]--[@b48-mjhid-11-1-e2019036],[@b50-mjhid-11-1-e2019036] were considered as A, one paper (12.50%)[@b45-mjhid-11-1-e2019036] as B, and one paper (12.50%)[@b49-mjhid-11-1-e2019036] as C, without D. The papers scored well on questions 1, 2, 3, 5, 6, 8, 9, and worse on questions 4, 7, 10.

The reason for that the answer of Walczak *et al*.[@b49-mjhid-11-1-e2019036] to question 4 was "NO" was as follows. Because β-thalassemia major patients with DFO treatment need lengthy infusions, the lengthy infusions cost much time, and which leads to much indirect cost, such as the productive loss, wages loss, *etc*. As a result, if a patient perspective for the analysis is adopted, the indirect cost will be essential and should be identified. However, Walczak *et al*.[@b49-mjhid-11-1-e2019036] adopted a patient perspective and did not identify the indirect cost. The answer of Karnon *et al*.[@b45-mjhid-11-1-e2019036] to question 7 was "NO" because the costs and consequences of this paper had no discount with a study time horizon of 50 years. The answer of Walczak *et al*.[@b49-mjhid-11-1-e2019036] to question 10 was "NO" because the paper of Walczak *et al*. had no discussion. The answer of Delea *et al*.,[@b34-mjhid-11-1-e2019036] Luangasanatip *et al*.,[@b35-mjhid-11-1-e2019036] Karnon *et al*.,[@b45-mjhid-11-1-e2019036] Bentley *et al*.,[@b46-mjhid-11-1-e2019036] Keshtkaran *et al*.,[@b48-mjhid-11-1-e2019036] Pepe *et al*.[@b50-mjhid-11-1-e2019036] to question 10 were "UNCERTAIN" because the discussion of these papers lacked some issues of concern to users. The papers of Delea *et al*.,[@b34-mjhid-11-1-e2019036] Luangasanatip *et al*.,[@b35-mjhid-11-1-e2019036] and Keshtkaran *et al*.[@b48-mjhid-11-1-e2019036] did not discuss the generalizability of their research results to other patients or settings. The paper of Pepe *et al*.[@b50-mjhid-11-1-e2019036] did not compare its research results with those of others who have investigated the same question. The papers of Karnon *et al*.[@b45-mjhid-11-1-e2019036] and Bentley *et al*.[@b46-mjhid-11-1-e2019036] did not discuss the impact of foreign utility data on their research results.

Economic evaluation
-------------------

a.  [DFX versus DFO]{.ul}. There were nine cost-utility analyses of DFX versus DFO. In three of nine studies,[@b34-mjhid-11-1-e2019036],[@b47-mjhid-11-1-e2019036],[@b49-mjhid-11-1-e2019036] the ΔQALY and ΔCOST were positive numbers, which meant that using DFX achieved better utility and a higher cost than when using DFO. Due to the lower ICERs of these three studies[@b34-mjhid-11-1-e2019036],[@b47-mjhid-11-1-e2019036],[@b49-mjhid-11-1-e2019036] than their payment threshold, the cost of using DFX was acceptable, and using DFX was cost-effective. In the three studies from two papers,[@b45-mjhid-11-1-e2019036],[@b48-mjhid-11-1-e2019036] the ΔQALY values were positive, whereas those of ΔCOST values were negative, which meant that using DFX led to a better utility and a lower cost compared the use of DFO. As a result, using DFX was cost-effective. In three other studies,[@b35-mjhid-11-1-e2019036],[@b46-mjhid-11-1-e2019036],[@b50-mjhid-11-1-e2019036] the ΔQALY and ΔCOST were positive numbers, and their ΔICER values were higher than their payment threshold, indicating that the cost of using DFX was unacceptable and suing DFO was more cost-effective.

b.  [DFX versus DFP]{.ul}. There were three cost-utility analyses of DFX versus DFP. In the three included studies, ΔQALY, and ΔCOST values determined by Luangasanatip *et al*.[@b35-mjhid-11-1-e2019036] were both positive numbers, so using DFX resulted in better utility and a higher cost than when using DFP. Unfortunately, the ΔICER of Luangasanatip *et al*.[@b35-mjhid-11-1-e2019036] was USD 106,409 and higher than its payment threshold. As a result, the cost of using DFX was unacceptable, and using DFP was cost-effective. In two other studies,[@b46-mjhid-11-1-e2019036],[@b50-mjhid-11-1-e2019036] ΔQALY values were negative, whereas those of ΔCOST were positive, showing that using DFX led to a worse utility and a higher cost as compared with the cases of using DFP. As a result, the DFX was not cost effective.

c.  [DFP versus DFO]{.ul}. There were three cost-utility analyses of DFP versus DFO. These three studies revealed that DFP was cost-effective in comparison with the utilization of DFO. In the study of Luangasanatip *et al*.,[@b35-mjhid-11-1-e2019036] ΔQALY value was zero and ΔCOST value was USD -9,117, which meant that using DFP led to the same utility and a lower cost compared the use of DFO, and using DFP was cost-effective. In two other studies,[@b46-mjhid-11-1-e2019036],[@b50-mjhid-11-1-e2019036] the ΔQALY values were positive, and ΔCOST values were negative, which meant that using DFP led to a better utility and a lower cost compared with using DFO. As a result, the DFP was not cost effective.

d.  [DFO + DFP versus DFO]{.ul}. Only one study[@b35-mjhid-11-1-e2019036] assessed that comparison. In the study of Luangasanatip *et al*.,[@b35-mjhid-11-1-e2019036] ΔQALY and ΔCOST were positive numbers, and the ΔICER was higher than the payment threshold. This outcome meant that the DFO+DFP led to a better utility and a higher cost compared with DFO monotherapy. Because the ΔICER was higher than its payment threshold, using DFO+DFP was unacceptable in Thailand, and using DFO monotherapy was established as cost-effective.

e.  [DFO + DFP versus DFP]{.ul}. In the only one study (Bentley *et al*.)[@b46-mjhid-11-1-e2019036] included in that category, ΔQALY value was negative, whereas ΔCOST value positive. This result indicated that the DFO+DFP had a worse utility and a higher cost compared with DFP monotherapy. Hence, using DFP monotherapy was more cost-effective.

f.  [DFO + DFP versus DFX]{.ul}. In the two studies[@b46-mjhid-11-1-e2019036],[@b50-mjhid-11-1-e2019036] in this group, ΔQALY and ΔCOST were both negative numbers, which meant the DFO+DFP led to a worse utility and a lower cost in comparison with DFX monotherapy. Therefore, it was impossible to be sure which of two chelation regimens was cost-effective. More related research is required for further analysis.

Sensitivity analyses
--------------------

Sensitivity analysis was not conducted in only one[@b49-mjhid-11-1-e2019036] out of eight papers. The details of the sensitivity analysis of the other seven papers can be found in [Table 1](#t1-mjhid-11-1-e2019036){ref-type="table"}. The sensitivity analysis of seven papers[@b34-mjhid-11-1-e2019036],[@b35-mjhid-11-1-e2019036],[@b45-mjhid-11-1-e2019036]--[@b48-mjhid-11-1-e2019036],[@b50-mjhid-11-1-e2019036] showed that the influential parameters were drug cost, DFO administration cost, drug compliance, the dose of the drug, the starting age of chelation therapy, the discount rate and the utility values associated with the route of administration or complication.

Discussion
==========

Four chelation regimens for β-thalassemia major therapy were assessed in the study, including DFO monotherapy, DFP monotherapy, DFX monotherapy, and DFO+DFP. The focus was placed on the economic parameters of the four chelation regimens in an attempt to find the best cost-effective option, which would serve as useful guidance in clinical practice. Nine cost-utility analysis of DFX versus DFO had contradictory results. Three cost-utility analysis of DFX versus DFP established that using DFP was cost-effective. Three cost-utility analysis of DFP versus DFO established that using DFP was cost-effective. One study of DFO+DFP versus DFO found that using DFO was cost-effective. One study of DFO+DFP versus DFP found that using DFP was cost-effective. Remarkably, there was only one study of DFO+DFP versus DFO (or DFP). The number of studies was too small to ensure the accuracy of the results. As a result, more extensive, high-quality research is required for further analysis and confirmation of these findings. There were two studies of DFO+DFP versus DFX, and their ΔQALY and ΔCOST values were negative numbers. Thus, it is impossible to be sure which one of two chelation regimens was cost-effective. Cost-effectiveness was relatively sensitive to the influential parameters were drug cost, DFO administration cost, drug compliance, the dose of the drug, the starting age of chelation therapy, the discount rate and the utility values associated with the route of administration or complication.

With the development of the times, the combined iron chelation therapy used in β-thalassemia major patients is gradually increasing. The Guidelines from the US, Italy, Australia, and China all recommended that β-thalassemia major patients with over iron-related cardiomyopathy should receive DFO+DFP.[@b29-mjhid-11-1-e2019036]--[@b31-mjhid-11-1-e2019036],[@b15-mjhid-11-1-e2019036] Unfortunately, this study showed that there are a little number of pharmacoeconomic studies on combined iron chelation therapy. So more research on its utility and pharmacoeconomic would be necessary.

As can be observed in [Table 2](#t2-mjhid-11-1-e2019036){ref-type="table"}, the cost the iron chelation varies substantially in different countries (regions). In the studies of DFX versus DFO, the ΔCOSTt values from the US, Thailand, Australia, Taiwan (China) and Italy were positive numbers, whereas the ΔCOSTt from Iran was a negative number. The main reason is that same drugs are priced differently in various countries (regions). The studies of Delea *et al*.[@b34-mjhid-11-1-e2019036] and Karnon *et al*.[@b45-mjhid-11-1-e2019036] showed that Exjade® (DFX) was priced at USD 89.49 per gram in the United States and GBP 33.60 per gram in Australia, as well as Desferal® (DFO), was priced at USD 35.77 per gram in the United States, and GBP 9.34 per gram in Australia. According to the rate of calculation of GBP 1 = USD 1.3085,[@b51-mjhid-11-1-e2019036] the price of Exjade® in the US was 2.04-fold higher than that in Australia, and the price of Desferal® in the US was 2.93-fold higher than that in Australia. The study of Luangasanatip *et al*.[@b35-mjhid-11-1-e2019036] also showed that the difference in drug costs when changing from deferoxamine to deferasirox resulted in an increase of over 400% in Thailand, whereas the cost of the drug increased only 100% in both US and UK settings.[@b34-mjhid-11-1-e2019036],[@b52-mjhid-11-1-e2019036] The price of the three iron chelators in the considered countries has been showed in [Table 4](#t4-mjhid-11-1-e2019036){ref-type="table"}. The more details about that same drugs are priced differently in various countries (regions) could be seen in [Table 4](#t4-mjhid-11-1-e2019036){ref-type="table"}.

It can also be seen in [Table 2](#t2-mjhid-11-1-e2019036){ref-type="table"} that the difference in the DFO administration cost varies considerably in different countries (regions). The DFO administration cost was USD 179,331 in the US[@b34-mjhid-11-1-e2019036] and USD9078 in Taiwan (China).[@b47-mjhid-11-1-e2019036] The price of DFO administration cost in the US was 19.75-fold higher than that in Taiwan (China). The reason for the considerable difference in the DFO administration costs in different countries (regions) may be that the prices of infusion equipment, such as infusion pumps, alcohol, and disposables are different in various countries (regions). The Annual cost of a pump, for example, was GBP 230 in Australia[@b45-mjhid-11-1-e2019036] but USD 85.1 in Iran.[@b48-mjhid-11-1-e2019036] The pump prices in Australia are, therefore, 3.54 times higher than those in Iran, calculated at a rate of GBP 1 = USD 1.3085.[@b51-mjhid-11-1-e2019036] [Table 2](#t2-mjhid-11-1-e2019036){ref-type="table"} also shows that the difference in payment threshold varies significantly in different countries (regions). The main reason for this difference is the economic level of the countries (regions). Ordinarily, more developed national economies have higher payment thresholds, and the ΔICER of a drug is more likely to be below the payment threshold. Because the economy of Thailand is relatively backward, its GDP per capita in 2011 was USD 5,539.49,[@b53-mjhid-11-1-e2019036] and its payment threshold was only USD 8,707. Hence, the study of Luangasanatip *et al*.[@b35-mjhid-11-1-e2019036] indicated that the ΔICER of DFX VS DFO was USD 90,618, and using DFX was not cost-effective in Thailand nevertheless, if Thailand had the same payment threshold as the US,[@b34-mjhid-11-1-e2019036] as high as USD 100,000, the results of Luangasanatip *et al*.[@b35-mjhid-11-1-e2019036] would be the opposite.

Based on the above-discussed findings, we can summarize that the specific region considered has a substantial influence on the economy of drugs. Therefore, when referring to the results of this study for clinical decision-making, clinicians need to consider the impact of local economies, price, and other factors. Meanwhile, health care experts from different countries (regions) can actively conduct relevant economic research and obtain valuable localized evidence.

To ensure the quality of the research, we excluded incomplete papers, such as abstracts of the meeting. As a result, there may be fewer data available for final research. Moreover, it may bias the results. The risk of a language bias seems minor based on the one non-English and non-Chinese paper excluded.

In this review, we had taken into consideration the utilization of chelating agents in thalassemia only, where we found more data available to perform an economic evaluation. However, the importance of these drugs and their cost is of rising concern considering that the iron chelation is more and more utilized in iron overload of Sickle Cell Diseases[@b54-mjhid-11-1-e2019036],[@b55-mjhid-11-1-e2019036],[@b56-mjhid-11-1-e2019036] and Myelodysplastic Syndromes.[@b57-mjhid-11-1-e2019036] The conclusions driven by us for the thalassemia patients could be useful to have an idea about the most rewarding utilization among the chelating agents also for these two diseases; however, specific studies are advisable.

Conclusions
===========

In brief, DFP is the best choice, followed by DFO or DFX, when an iron chelator is to be used alone for β-thalassemia major therapy. All studies that compared DFO+DFP with DFO (or DFP) monotherapy established that the DFO+DFP was not cost-effective. Moreover, existing studies about DFO+DFP versus DFX could not prove which one of two chelation regimens was cost-effective. However, due to the low number of DFO+DFP versus DFO (or DFP or DFX) monotherapy studies, more extensive, high-quality research is required for further analysis and confirmation of our findings.

Moreover, the evaluation of cost-effectiveness, even being a global problem, cannot have a unique solution when in the different countries (regions) the results are opposite. The specific legislation of regions, where clinicians operate, had a substantial influence on the economy of drugs. Health care experts can contribute significantly to fully elucidating these aspects by conducting localized economic research, which will facilitate the choice of the best approach in each specific location.
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###### 

The characters of included papers.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                                       Country      Study Type                                                Perspective                                                                 Study Method            Time Horizon (year)   Health State                                                                                                                  Cost                                                                                                                                                                                           Sensitivity Analysis
  ---------------------------------------------- ------------ --------------------------------------------------------- --------------------------------------------------------------------------- ----------------------- --------------------- ----------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------
  Delea 2007[@b34-mjhid-11-1-e2019036]           US           CUA[\*](#tfn1-mjhid-11-1-e2019036){ref-type="table-fn"}   Health service                                                              Markov model            50                    β-thalassemia with cardiac complication, β-thalassemia without cardiac complication and death                                 **direct medical cost:** chelation, DFO administration, complication therapies(treatment of iron overload-related cardiac disease)                                                             One-way & two-way & probabilistic

  Luangasanatip 2011[@b35-mjhid-11-1-e2019036]   Thailand     CUA                                                       Society                                                                     Markov model            lifetime              β-thalassemia with cardiac complication, β-thalassemia without cardiac complication and death                                 **direct medical cost:** chelation, cost of a medical visit, DFO administration, adverse events management cost, complication therapies(treatment of iron overload-related cardiac disease)\   One-way & probabilistic
                                                                                                                                                                                                                                                                                                                                                                                **direct non-medical cost:** transportation cost additional food cost, caregiver cost\                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                **indirect cost:** productivity                                                                                                                                                                

  Karnon 2012[@b45-mjhid-11-1-e2019036]          Australian   CUA                                                       Health service                                                              Markov model            50                    β-thalassemia with cardiac and endocrine complications, β-thalassemia without cardiac and endocrine complications and death   **direct medical cost:** chelation, adverse events management cost, additional monitoring, complication therapies                                                                              One-way & Multi-way & probabilistic

  Bentley 2013[@b46-mjhid-11-1-e2019036]         UK           CUA                                                       Health service                                                              Markov model            5                     β-thalassemia with cardiac complication, β-thalassemia without cardiac complication and death                                 **direct medical cost:** chelation, DFO administration, monitoring, adverse events management cost                                                                                             One-way & two-way & probabilistic

  Ho 2013[@b47-mjhid-11-1-e2019036]              China\       CUA                                                       Health service                                                              Markov model            50                    β-thalassemia with complications, β-thalassemia without complications and death                                               **direct medical cost:** chelation, DFO administration, complication therapies                                                                                                                 One-way
                                                 Taiwan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Keshtkaran 2013[@b48-mjhid-11-1-e2019036]      Iran         CUA                                                       Society                                                                     Markov model            lifetime              β-thalassemia with cardiac complication, β-thalassemia without cardiac complication and death                                 **direct medical cost:** chelation, DFO administration, adverse events management cost, complication therapies(treatment of iron overload-related cardiac disease)\                            One-way & probabilistic
                                                                                                                                                                                                                                                                                                                                                                                **indirect cost:** transfusion time                                                                                                                                                            

  Walczak 2013[@b49-mjhid-11-1-e2019036]         Poland       CUA                                                       NHF[\#](#tfn2-mjhid-11-1-e2019036){ref-type="table-fn"} & patient and NHF   Simple decision model   1                     \-                                                                                                                            **direct medical cost:** chelation, DFO administration, Cost of hospitalizations for monitoring and blood transfusions, Cost of blood units, Cost of additional monitoring                     \-

  Pepe 2017[@b50-mjhid-11-1-e2019036]            Italy        CUA                                                       Health service                                                              Markov model            5                     β-thalassemia with cardiac complication, β-thalassemia without cardiac complication and death                                 **direct medical cost:** chelation, DFO administration, monitoring                                                                                                                             One-way & two-way & probabilistic
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CUA: cost-utility analyses

NHF: Polish National Health Fund.

###### 

The results of included studies.

  study ID                                                                                        Age     Discount (%)   currency[\*](#tfn3-mjhid-11-1-e2019036){ref-type="table-fn"}   ΔCOST   ΔQALY     ICER (ΔCOST/ΔQALY)   Payment threshold   Conflicts of interest                                                 
  ----------------------------------------------------------------------------------------------- ------- -------------- -------------------------------------------------------------- ------- --------- -------------------- ------------------- ----------------------- ------- -------- -------- ---------- -------- ----------------
  **DFX VS DFO**                                                                                                                                                                                                                                                                                                         
  Delea 2007[@b34-mjhid-11-1-e2019036]                                                            3       3              3                                                              USD     313823    −179331              −8474                                               126018   4.500    28255      100000   Novartis Parma
  Luangasanatip 2011[@b35-mjhid-11-1-e2019036]                                                    6       3              3                                                              USD     526996    −3679                                    −453                    0       522863   5.770    90618      8707     No conflicts
  Karnon 2012[@b45-mjhid-11-1-e2019036]                                                           6       \-             \-                                                             GBP     102017    −170533              −3573                                               −72089   4.850    −14864     \-       Novartis Parma
  Karnon 2012[@b45-mjhid-11-1-e2019036]                                                           2       \-             \-                                                             GBP     91745     −171190              −3399                                               −82846   5.020    −16503     \-       Novartis Parma
  Bentley 2013[@b46-mjhid-11-1-e2019036]                                                          \-      3.5            3.5                                                            GBP     80670     −44429               −1321                                               34921    0.813    42953      20000    ApoPharma
  Ho 2013[@b47-mjhid-11-1-e2019036]                                                               2       3              3                                                              USD     46889     −9078                −1519                                               36291    2.300    15596      100000   \-
  Keshtkaran 2013[@b48-mjhid-11-1-e2019036] [%](#tfn5-mjhid-11-1-e2019036){ref-type="table-fn"}   \-      5              3                                                              USD     −2772     −415.9               358                                         −4525   −96493   4.520    −21348     39159    No conflicts
  Walczak 2013[@b49-mjhid-11-1-e2019036]                                                          2--15                                                                                 PLN     4376                           336                                                 4712     0.180    26180      105801   \-
  Pepe 2017[@b50-mjhid-11-1-e2019036]                                                             \-      3              3                                                              EUR     103113    −12034               707                                                 91787    0.826    111118     20000    ApoPharma
                                                                                                                                                                                                                                                                                                                         
  **DFX VS DFP**                                                                                                                                                                                                                                                                                                         
  Luangasanatip 2011[@b35-mjhid-11-1-e2019036]                                                    6       3              3                                                              USD     614067    −39                                      −48                     0       613980   5.7700   106409     8707     No conflicts
  Bentley 2013[@b46-mjhid-11-1-e2019036]                                                          \-      3.5            3.5                                                            GBP     80497     0                    −327                                                80172    −0.099   −809818    20000    ApoPharma
  pepe 2017[@b50-mjhid-11-1-e2019036]                                                             \-      3              3                                                              EUR     134021    0                    218                                                 134240   −0.107   −1254579   20000    ApoPharma
                                                                                                                                                                                                                                                                                                                         
  **DFP VS DFO**                                                                                                                                                                                                                                                                                                         
  Luangasanatip 2011[@b35-mjhid-11-1-e2019036]                                                    6       3              3                                                              USD     −87071    −3640                                    −406                    0       −9117    0        Dominant   8707     No conflicts
  Bentley 2013[@b46-mjhid-11-1-e2019036]                                                          \-      3.5            3.5                                                            GBP     173       −44429               −994                                                −45251   0.912    −49617     20000    ApoPharma
  Pepe 2017[@b50-mjhid-11-1-e2019036]                                                             \-      3              3                                                              EUR     −30908    −12034               489                                                 −42453   0.933    −45502     20000    ApoPharma
                                                                                                                                                                                                                                                                                                                         
  **DFO+DFP VS DFO**                                                                                                                                                                                                                                                                                                     
  Bentley 2013[@b46-mjhid-11-1-e2019036]                                                          \-      3.5            3.5                                                            GBP     21034     −8226                −1025                                               14205    0.240    59093      20000    ApoPharma
                                                                                                                                                                                                                                                                                                                         
  **DFO+DFP VS DFP**                                                                                                                                                                                                                                                                                                     
  Bentley 2013[@b46-mjhid-11-1-e2019036]                                                          \-      3.5            3.5                                                            GBP     20861     36203                2391                                                59456    −0.672   −88476     20000    ApoPharma
                                                                                                                                                                                                                                                                                                                         
  **DFO+DFP VS DFX**                                                                                                                                                                                                                                                                                                     
  Karnon 2012[@b45-mjhid-11-1-e2019036] (high-dose DFX)                                           6       \-             \-                                                             GBP     −144599   127388               4902                                                −12310   −2.500   4925       \-       Novartis Parma
  Bentley 2013[@b46-mjhid-11-1-e2019036]                                                          \-      3.5            3.5                                                            GBP     −59636    36203                2718                                                −20716   −0.573   36154      20000    ApoPharma

USD: United States dollar, GBP: Great Britain Pound, EUR: European Dollar, PLN: Polish Zloty.

ΔCOST~t~=Δdirect medical care costs+Δdirect non-medical care cost+Δindirect cost.

Annual cost.

###### 

Results of the methodological quality assessment[\*](#tfn6-mjhid-11-1-e2019036){ref-type="table-fn"}

                                                 Question[\#](#tfn7-mjhid-11-1-e2019036){ref-type="table-fn"}   Point   Rating                                     
  ---------------------------------------------- -------------------------------------------------------------- ------- -------- --- --- --- --- --- --- ---- ---- ---
  Delea 2007[@b34-mjhid-11-1-e2019036]           Y                                                              Y       Y        Y   Y   Y   Y   Y   Y   UN   9    A
  Luangasanatip 2011[@b35-mjhid-11-1-e2019036]   Y                                                              Y       Y        Y   Y   Y   Y   Y   Y   UN   9    A
  Karnon 2012[@b45-mjhid-11-1-e2019036]          Y                                                              Y       Y        Y   Y   Y   N   Y   Y   UN   8    B
  Bentley 2013[@b46-mjhid-11-1-e2019036]         Y                                                              Y       Y        Y   Y   Y   Y   Y   Y   UN   9    A
  Ho 2013[@b47-mjhid-11-1-e2019036]              Y                                                              Y       Y        Y   Y   Y   Y   Y   Y   Y    10   A
  Keshtkaran 2013[@b48-mjhid-11-1-e2019036]      Y                                                              Y       Y        Y   Y   Y   Y   Y   Y   UN   9    A
  Walczak 2013[@b49-mjhid-11-1-e2019036]         Y                                                              Y       Y        N   Y   Y   Y   Y   N   N    7    C
  Pepe 2017[@b50-mjhid-11-1-e2019036]            Y                                                              Y       Y        Y   Y   Y   Y   Y   Y   UN   9    A

Y: yes, N: no, UN: uncertain.

Question: (1) Was a well-defined question posed in answerable form? (2) Was a comprehensive description of the competing alternatives given? (3) Was the effectiveness of the programs or services established? (4) Were all the important and relevant costs, and consequences for each alternative identified? (5) Were costs and consequences measured accurately in the appropriate physical units prior to valuation? (6) Were costs and consequences valued credibly? (7) Were costs and consequences adjusted for differential timing? (8)Was and incremental analysis of costs and consequences of alternatives performed? (9) Was uncertainty in the estimates of costs and consequences adequately characterized? (10) Did the presentation and discussion of study results include all issues of concern to users?

###### 

The price of the three iron chelators in the considered countries.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                                       Country                 the price of iron chelators (per gram) (USD[\*](#tfn8-mjhid-11-1-e2019036){ref-type="table-fn"})                                                                                      
  ---------------------------------------------- ----------------------- -------------------------------------------------------------------------------------------------- ----------------------- ------------------------ --------------------- ----------- -----------------------
  Delea 2007[@b20-mjhid-11-1-e2019036]           US                      Desferal^®^                                                                                        USD 35.77                                                              Exjade^®^   USD 89.49

  Luangasanatip 2011[@b21-mjhid-11-1-e2019036]   Thailand                Desferal^®^                                                                                        USD 10.77               Kelfer^®^\               USD 2.09\             Exjade^®^   USD 58.56
                                                                                                                                                                                                    GPO-L-ONE^®^             USD 0.20                          

  Karnon 2012[@b24-mjhid-11-1-e2019036]          Australian              generic\                                                                                           USD 8.52\               Ferriprox^®^             USD 3.04              Exjade^®^   USD 33.60
                                                                         Desferal^®^                                                                                        USD 9.34                                                                           

  Bentley 2013[@b25-mjhid-11-1-e2019036]         UK                      generic                                                                                            GBP 8.50 (USD 11.12)    Ferriprox^®^             GBP 3.20 (USD 4.19)   Exjade^®^   GBP 33.60 (USD 43.97)

  Ho 2013[@b26-mjhid-11-1-e2019036]              China\                                                                                                                     USD 20.00                                                                          USD 60.70
                                                 Taiwan                                                                                                                                                                                                        

  Keshtkaran 2013[@b27-mjhid-11-1-e2019036]      Iran                    \-                                                                                                 \-                      \-                       \-                    \-          \-

  Walczak 2013[@b28-mjhid-11-1-e2019036]         Poland                  \-                                                                                                 \-                                                                     Exjade^®^   PLN 6.94 (USD 1.89)

  Pepe 2017[@b29-mjhid-11-1-e2019036]            Italy                   Desferal^®^ (injection, 500mg/10ml)                                                                EUR 10.90 (USD 12.69)   Ferriprox^®^ (tablets)   EUR 2.90 (USD 3.38)   Exjade^®^   EUR 52.00 (USD 60.56)

  Desferal^®^(injection, 2g/                     EUR 27.20 (USD 31.68)   Ferriprox (oral solution)^®^                                                                       EUR 3.60 (USD 4.19)                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GBP 1 = USD 1.3085, EUR 1 = USD 1.1646, PLN 1 = USD 0.2727
